Levetiracetam Altan Pharma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal firing and diminishes hyper‑excitability, thereby preventing the spread of seizure activity across the brain.

The appropriate dose of Levetiracetam is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. No fixed regimen can be stated without a medical prescription.

Levetiracetam is classified as Pregnancy Category B1, indicating no evidence of risk in animal studies and a lack of well‑controlled human data. It should be used only if the potential benefit justifies the potential risk, and breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with older agents such as carbamazepine or valproic acid, levetiracetam has a distinct mechanism (SV2A binding) and a relatively favorable drug‑interaction profile. It is often chosen for patients who require fewer metabolic interactions, though individual efficacy and tolerability vary and should be assessed by the treating physician.

Levetiracetam for injection should be stored at 2‑8 °C (refrigerated). Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial. Once removed from refrigeration, use according to the manufacturer’s stability guidelines.

Levetiracetam is supplied as an intravenous solution that is administered by slow infusion under medical supervision. The exact infusion rate and total daily dose are determined by the prescriber, taking into account the patient’s clinical condition and renal function.

Serious adverse events include severe allergic reactions such as rash or anaphylaxis, rare skin conditions like Stevens‑Johnson syndrome, and neuropsychiatric effects such as emergence of suicidal thoughts or severe depression. Prompt medical attention is required if any of these symptoms occur.

Patients with a known hypersensitivity to levetiracetam or any component of the intravenous formulation should avoid its use. Caution is also advised in individuals with severe renal impairment, and the drug should be prescribed only after a thorough assessment of potential contraindications.